# aTYR PHARMA INC: filings

ATYR · Nasdaq · CIK 1339970 · [Healthcare](/sectors/healthcare.md) · fiscal year ends Dec 31

Pages: [Overview](/companies/atyr.md) · [Financials](/companies/atyr/financials.md) · [Filings](/companies/atyr/filings.md) · [Insiders](/companies/atyr/insiders.md)

## Reports and events: 219 filings

Newest first, by EDGAR acceptance time (Eastern). Filter with ?form= one of: `periodic`, `8-K`, `10-K`, `10-Q`, `4`, `proxy`, `13dg`, `all`, or any form this company filed (4 281, 8-K 142, 3 43, SC 13G/A 38, 10-Q 35, SC 13G 20, CORRESP 17, DEFA14A 15, UPLOAD 14, 424B5 13, DEF 14A 12, S-8 12, 10-K 11, EFFECT 11, PRE 14A 8, S-3 8, CT ORDER 5, S-1/A 5, SC 13D/A 5, ARS 4, SCHEDULE 13G/A 4, 4/A 3, S-1 3, SC 13D 3, 3/A 2, 424B4 2, 8-K/A 2, D 2, DRSLTR 2, 10-Q/A 1, 424B3 1, 8-A12B 1, CERTNAS 1, DRS 1, DRS/A 1, POS EX 1, S-1MEF 1, S-3/A 1, S-3MEF 1, SCHEDULE 13G 1).

| Filed | Accepted | Form | What it is | Accession |
| --- | --- | --- | --- | --- |
| 2026-10-27 | 09:03 ET | [8-K](/filings/0001339970-26-000071.md) | 5.03 Amendment to articles or bylaws; 9.01 Financial statements and exhibits | 0001339970-26-000071 |
| 2026-10-16 | 16:02 ET | [8-K](/filings/0001339970-26-000068.md) | 5.07 Shareholder vote results | 0001339970-26-000068 |
| 2026-09-24 | 07:47 ET | [8-K](/filings/0001339970-26-000065.md) | 8.01 Other events | 0001339970-26-000065 |
| 2026-09-11 | 16:06 ET | [DEF 14A](/filings/0001339970-26-000061.md) | Proxy statement, period 2026-10-16 | 0001339970-26-000061 |
| 2026-08-07 | 16:07 ET | [10-Q](/filings/0001339970-26-000053.md) | Quarterly report, period 2026-06-30 | 0001339970-26-000053 |
| 2026-08-07 | 16:04 ET | [8-K](/filings/0001339970-26-000051.md) | 2.02 Results of operations; 9.01 Financial statements and exhibits | 0001339970-26-000051 |
| 2026-07-31 | 16:44 ET | [8-K](/filings/0001339970-26-000042.md) | 1.02 Termination of a material agreement; 9.01 Financial statements and exhibits | 0001339970-26-000042 |
| 2026-06-08 | 16:04 ET | [8-K](/filings/0001339970-26-000039.md) | 3.01 Delisting notice | 0001339970-26-000039 |
| 2026-06-01 | 16:04 ET | [8-K](/filings/0001339970-26-000036.md) | 7.01 Regulation FD disclosure; 9.01 Financial statements and exhibits | 0001339970-26-000036 |
| 2026-05-15 | 16:01 ET | [10-Q](/filings/0001339970-26-000033.md) | Quarterly report, period 2026-03-31 | 0001339970-26-000033 |
| 2026-05-15 | 08:02 ET | [8-K](/filings/0001339970-26-000030.md) | 2.02 Results of operations; 9.01 Financial statements and exhibits | 0001339970-26-000030 |
| 2026-05-11 | 16:03 ET | [8-K](/filings/0001339970-26-000027.md) | 2.02 Results of operations; 7.01 Regulation FD disclosure; 8.01 Other events; 9.01 Financial statements and exhibits | 0001339970-26-000027 |
| 2026-03-26 | 16:08 ET | [DEF 14A](/filings/0001339970-26-000021.md) | Proxy statement, period 2026-03-26 | 0001339970-26-000021 |
| 2026-03-05 | 16:11 ET | [10-K](/filings/0001339970-26-000008.md) | Annual report, period 2025-12-31 | 0001339970-26-000008 |
| 2026-03-05 | 16:03 ET | [8-K](/filings/0001339970-26-000006.md) | 2.02 Results of operations; 9.01 Financial statements and exhibits | 0001339970-26-000006 |
| 2025-12-05 | 16:05 ET | [8-K](/filings/0001193125-25-309619.md) | 3.01 Delisting notice | 0001193125-25-309619 |
| 2025-11-06 | 16:17 ET | [10-Q](/filings/0001193125-25-269587.md) | Quarterly report, period 2025-09-30 | 0001193125-25-269587 |
| 2025-11-06 | 16:08 ET | [8-K](/filings/0001193125-25-269486.md) | 2.02 Results of operations; 9.01 Financial statements and exhibits | 0001193125-25-269486 |
| 2025-09-15 | 08:30 ET | [8-K](/filings/0001193125-25-202865.md) | 8.01 Other events; 9.01 Financial statements and exhibits | 0001193125-25-202865 |
| 2025-08-08 | 21:33 ET | [8-K/A](/filings/0001339970-25-000016.md) | 2.02 Results of operations; 9.01 Financial statements and exhibits | 0001339970-25-000016 |
| 2025-08-07 | 16:07 ET | [10-Q](/filings/0001339970-25-000009.md) | Quarterly report, period 2025-06-30 | 0001339970-25-000009 |
| 2025-08-07 | 16:03 ET | [8-K](/filings/0001339970-25-000007.md) | 2.06 Material impairments; 9.01 Financial statements and exhibits | 0001339970-25-000007 |
| 2025-05-07 | 16:07 ET | [10-Q](/filings/0000950170-25-065640.md) | Quarterly report, period 2025-03-31 | 0000950170-25-065640 |
| 2025-05-07 | 16:03 ET | [8-K](/filings/0000950170-25-065611.md) | 2.02 Results of operations; 9.01 Financial statements and exhibits | 0000950170-25-065611 |
| 2025-05-06 | 16:01 ET | [8-K](/filings/0000950170-25-064413.md) | 5.02 Departure or appointment of officers or directors; 5.07 Shareholder vote results; 9.01 Financial statements and exhibits | 0000950170-25-064413 |
| 2025-03-19 | 16:08 ET | [DEF 14A](/filings/0000950170-25-041992.md) | Proxy statement, period 2025-03-19 | 0000950170-25-041992 |
| 2025-03-13 | 17:19 ET | [10-K](/filings/0000950170-25-038888.md) | Annual report, period 2024-12-31 | 0000950170-25-038888 |
| 2025-03-13 | 16:03 ET | [8-K](/filings/0000950170-25-038703.md) | 2.02 Results of operations; 9.01 Financial statements and exhibits | 0000950170-25-038703 |
| 2024-12-23 | 16:42 ET | [8-K](/filings/0000950170-24-139633.md) | 1.01 Entry into a material agreement; 9.01 Financial statements and exhibits | 0000950170-24-139633 |
| 2024-12-12 | 16:05 ET | [8-K](/filings/0000950170-24-135766.md) | 5.02 Departure or appointment of officers or directors; 9.01 Financial statements and exhibits | 0000950170-24-135766 |
| 2024-11-07 | 16:07 ET | [10-Q](/filings/0000950170-24-123305.md) | Quarterly report, period 2024-09-30 | 0000950170-24-123305 |
| 2024-11-07 | 16:03 ET | [8-K](/filings/0000950170-24-123256.md) | 2.02 Results of operations; 9.01 Financial statements and exhibits | 0000950170-24-123256 |
| 2024-08-13 | 16:07 ET | [10-Q](/filings/0000950170-24-096185.md) | Quarterly report, period 2024-06-30 | 0000950170-24-096185 |
| 2024-08-13 | 16:02 ET | [8-K](/filings/0000950170-24-096139.md) | 2.02 Results of operations; 9.01 Financial statements and exhibits | 0000950170-24-096139 |
| 2024-07-22 | 08:30 ET | [8-K](/filings/0000950170-24-085058.md) | 8.01 Other events | 0000950170-24-085058 |
| 2024-05-29 | 16:03 ET | [8-K](/filings/0000950170-24-065899.md) | 5.02 Departure or appointment of officers or directors; 5.05 Item not in the standard list; 5.07 Shareholder vote results; 8.01 Other events; 9.01 Financial statements and exhibits | 0000950170-24-065899 |
| 2024-05-02 | 16:07 ET | [10-Q](/filings/0000950170-24-052092.md) | Quarterly report, period 2024-03-31 | 0000950170-24-052092 |
| 2024-05-02 | 16:04 ET | [8-K](/filings/0000950170-24-052058.md) | 2.02 Results of operations; 9.01 Financial statements and exhibits | 0000950170-24-052058 |
| 2024-04-05 | 16:00 ET | [DEF 14A](/filings/0000950170-24-042236.md) | Proxy statement, period 2024-05-22 | 0000950170-24-042236 |
| 2024-03-14 | 16:38 ET | [10-K](/filings/0000950170-24-031584.md) | Annual report, period 2023-12-31 | 0000950170-24-031584 |
| 2024-03-14 | 16:01 ET | [8-K](/filings/0000950170-24-031441.md) | 2.02 Results of operations; 9.01 Financial statements and exhibits | 0000950170-24-031441 |
| 2023-11-09 | 16:11 ET | [10-Q](/filings/0000950170-23-062058.md) | Quarterly report, period 2023-09-30 | 0000950170-23-062058 |
| 2023-11-09 | 16:06 ET | [8-K](/filings/0000950170-23-062020.md) | 2.02 Results of operations; 9.01 Financial statements and exhibits | 0000950170-23-062020 |
| 2023-09-26 | 09:01 ET | [8-K](/filings/0000950170-23-049802.md) | 7.01 Regulation FD disclosure; 8.01 Other events; 9.01 Financial statements and exhibits | 0000950170-23-049802 |
| 2023-09-11 | 08:04 ET | [8-K](/filings/0000950170-23-047360.md) | 8.01 Other events | 0000950170-23-047360 |
| 2023-08-09 | 16:14 ET | [10-Q](/filings/0000950170-23-040598.md) | Quarterly report, period 2023-06-30 | 0000950170-23-040598 |
| 2023-08-09 | 16:10 ET | [8-K](/filings/0000950170-23-040581.md) | 2.02 Results of operations; 9.01 Financial statements and exhibits | 0000950170-23-040581 |
| 2023-05-19 | 16:17 ET | [8-K](/filings/0000950170-23-023257.md) | 5.02 Departure or appointment of officers or directors; 5.03 Amendment to articles or bylaws; 5.05 Item not in the standard list; 5.07 Shareholder vote results; 9.01 Financial statements and exhibits | 0000950170-23-023257 |
| 2023-05-09 | 16:14 ET | [10-Q](/filings/0000950170-23-019686.md) | Quarterly report, period 2023-03-31 | 0000950170-23-019686 |
| 2023-05-09 | 16:07 ET | [8-K](/filings/0000950170-23-019633.md) | 2.02 Results of operations; 9.01 Financial statements and exhibits | 0000950170-23-019633 |

Page 1 of 5. [Older](/companies/atyr/filings.md?page=2)
Source: SEC EDGAR, the company’s filing index. Last ingested by Listed: Oct 27, 2026, 09:04 ET. No prices; not investment advice.